期刊
NATURE
卷 603, 期 7899, 页码 95-+出版社
NATURE PORTFOLIO
DOI: 10.1038/s41586-022-04394-w
关键词
-
资金
- Business Finland [HUS 4685/31/2016, UH 4386/31/2016]
- AbbVie
- AstraZeneca UK
- Biogen MA
- Celgene
- Celgene International II
- Genentech
- Merck Sharp Dohme
- Pfizer
- GlaxoSmithKline Intellectual Property Development
- Sanofi US Services
- Maze Therapeutics
- Janssen Biotech
- Novartis
- National Natural Science Fund of China [81070153]
- Personnel Development Foundation of Shanghai, China [2010019]
- Key Program of Basic Research of Shanghai, China [10JC1414002]
- Canadian Institutes of Health Research [MOP-111072, MOP-130373]
- French Ministry of Research and Technology (MRT)
This study combines sequencing and genotyping data from two population biobanks to identify genetic associations with human diseases in the rare and low-frequency allelic spectrum, providing insights into disease biology and biomarker levels.
Genome-wide association studies (GWAS) have identified thousands of genetic variants linked to the risk of human disease. However, GWAS have so far remained largely underpowered in relation to identifying associations in the rare and low-frequency allelic spectrum and have lacked the resolution to trace causal mechanisms to underlying genes(1). Here we combined whole-exome sequencing in 392,814 UK Biobank participants with imputed genotypes from 260,405 FinnGen participants (653,219 total individuals) to conduct association meta-analyses for 744 disease endpoints across the protein-coding allelic frequency spectrum, bridging the gap between common and rare variant studies. We identified 975 associations, with more than one-third being previously unreported. We demonstrate population-level relevance for mutations previously ascribed to causing single-gene disorders, map GWAS associations to likely causal genes, explain disease mechanisms, and systematically relate disease associations to levels of 117 biomarkers and clinical-stage drug targets. Combining sequencing and genotyping in two population biobanks enabled us to benefit from increased power to detect and explain disease associations, validate findings through replication and propose medical actionability for rare genetic variants. Our study provides a compendium of protein-coding variant associations for future insights into disease biology and drug discovery. A meta-analysis combining whole-exome sequencing data from UK Biobank participants and imputed genotypes from FinnGen participants enables identification of genetic associations with human disease in the rare and low-frequency allelic spectrum
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据